Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafuramycin-A (Griffith University)
- Development stage
- Unknown
- Lead developer
- Griffith University
- Modality
- Small Molecules
01
Overview
Tafuramycin-A (TF-A) is a seco-cyclopropyl pyrrolo indole analogue and a duocarmycin-SA derivative that acts as a potent DNA alkylating agent. It irreversibly binds to and alkylates DNA, specifically targeting A-T rich regions. TF-A is primarily utilized as a chemical attenuating agent to prepare whole-parasite blood-stage malaria vaccines (such as attenuated *Plasmodium falciparum* parasites), preventing parasite replication while preserving immunogenicity. Additionally, it has been investigated preclinically for its cytotoxic and anticancer properties, particularly against breast cancer.
- Other names
- tafuramycin A
02
Targets
DNA
Beyond the preview
Go deeper on tafuramycin-A (Griffith University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafuramycin-A (Griffith University).